TransCode Therapeutics is an RNA oncology company developing RNA-based therapeutics for cancer treatment. Its proprietary TTX drug delivery platform enables targeted delivery of oligonucleotides to tumors and metastases. Its lead candidate, TTX-MC138, targets microRNA-10b, a regulator of metastatic cell viability across multiple cancers including breast, pancreatic, ovarian, and colon. The company has received FDA authorization and is conducting a Phase I/II clinical trial with TTX-MC138 in patients with advanced solid tumors.
expected 2026-12-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001558370-25-004843 | EDGAR | 112K words |
| 2024-04-01 | 2023-12-31 | 0001410578-24-000413 | EDGAR | 111K words |
| 2023-03-31 | 2022-12-31 | 0001104659-23-040158 | EDGAR | 104K words |
| 2022-03-31 | 2021-12-31 | 0001104659-22-040778 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001829635-26-000003 | EDGAR | 47K words |
| 2025-11-14 | 2025-09-30 | 0001829635-25-000004 | EDGAR | 38K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011571 | EDGAR | 31K words |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007759 | EDGAR | 29K words |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015731 | EDGAR | 30K words |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012264 | EDGAR | 31K words |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008298 | EDGAR | 29K words |
| 2023-11-14 | 2023-09-30 | 0001410578-23-002489 | EDGAR | 31K words |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001892 | EDGAR | 29K words |
| 2023-05-15 | 2023-03-31 | 0001104659-23-060810 | EDGAR | 26K words |
| 2022-11-14 | 2022-09-30 | 0001104659-22-118641 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001104659-22-091201 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-28 | 0001104659-26-111170 | EDGAR | 1K words |
| 2026-09-11 | 0001104659-26-107115 | EDGAR | 5K words |
| 2026-08-03 | 0001104659-26-089805 | EDGAR | 8K words |
| 2026-07-20 | 0001104659-26-085073 | EDGAR | 1K words |
| 2026-07-17 | 0001104659-26-084617 | EDGAR | 6K words |
| 2026-03-03 | 0001104659-26-022830 | EDGAR | 6K words |
| 2026-02-23 | 0001104659-26-018362 | EDGAR | 1K words |
| 2026-02-05 | 0001104659-26-010668 | EDGAR | 1K words |
| 2026-01-06 | 0001104659-26-001097 | EDGAR | 1K words |
| 2025-12-22 | 0001104659-25-123500 | EDGAR | 1K words |
135 total filings indexed. 109 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001829635 |
| Ticker | RNAZ |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.transcodetherapeutics.com |
| Listed | 2021-07-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RNAZ (~200 tokens, structured JSON with cryptographic provenance)